Payment overview · 2025
General Payments
$186.77
9 reported records · 6 companies
Healthcare provider profile · identity verified
Jason Valls, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT MARTINVILLE, LA · NPI 1245267244
Verified facts
What the public records show
CMS Open Payments records show Jason Valls, MD received $186.77 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.61 | 35.7% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $41.49 | 22.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.57 | 14.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.67 | 10.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.76 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.67 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.77 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.61 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 95 |
| Gabapentin | Gabapentin | 359 | 67 |
| Losartan Potassium | Losartan Potassium | 341 | 68 |
| Metformin Hcl | Metformin Hcl | 309 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 41 |
| Omeprazole | Omeprazole | 242 | 49 |
| Lisinopril | Lisinopril | 224 | 42 |
| Alprazolam | Alprazolam | 208 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 37 |
| Ozempic | Semaglutide | 187 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 184 | 73 |
| Carvedilol | Carvedilol | 169 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 29 |
| Meloxicam | Meloxicam | 140 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 24 |
| Famotidine | Famotidine | 124 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 24 |
| Alendronate Sodium | Alendronate Sodium | 111 | 21 |
| Glipizide | Glipizide | 111 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 23 |
| Ibuprofen | Ibuprofen | 107 | 37 |
| Potassium Chloride | Potassium Chloride | 99 | 20 |
| Indomethacin | Indomethacin | 97 | 30 |
| Tramadol Hcl | Tramadol Hcl | 97 | 31 |
| Glimepiride | Glimepiride | 96 | 18 |
| Jardiance | Empagliflozin | 96 | 16 |
| Azithromycin | Azithromycin | 90 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 17 |
| Allopurinol | Allopurinol | 81 | 13 |
| Linzess | Linaclotide | 77 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 13 |
| Furosemide | Furosemide | 73 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | suppressed |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Lorazepam | Lorazepam | 68 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 13 |
| Ketoconazole | Ketoconazole | 63 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 12 |
| Montelukast Sodium | Montelukast Sodium | 57 | 12 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Pregabalin | Pregabalin | 49 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Eliquis | Apixaban | 42 | suppressed |
| Simvastatin | Simvastatin | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 40 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Calcipotriene | Calcipotriene | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Prednisone | Prednisone | 26 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Atenolol | Atenolol | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Euthyrox | Levothyroxine Sodium | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Unithroid | Levothyroxine Sodium | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Nifedipine | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.77 · 9 records | ABBVIE INC. | AIRSUPRA, IBSRELA, JARDIANCE, MINIMED 780G, VRAYLAR, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error